Global Finance News
03 Apr 2026, 11:36
Gilead Sciences announced it has extended its tender offer to acquire Arcellx, pushing the deadline to April 24, 2026.
The offer remains at $115 per share in cash plus a contingent value right (CVR) that could provide an additional $5 per share if future sales milestones are met. As of March 31, about 7.5% of Arcellx shares had been tendered.
The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and other customary conditions, including majority shareholder participation.
Gilead said the extension allows additional time for shareholders to participate as it continues efforts to complete the transaction and strengthen its oncology pipeline.
Business Wire
The offer remains at $115 per share in cash plus a contingent value right (CVR) that could provide an additional $5 per share if future sales milestones are met. As of March 31, about 7.5% of Arcellx shares had been tendered.
The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and other customary conditions, including majority shareholder participation.
Gilead said the extension allows additional time for shareholders to participate as it continues efforts to complete the transaction and strengthen its oncology pipeline.
Business Wire